The functional mechanism of simvastatin in experimental osteoporosis

详细信息    查看全文

• 作者：Lifen Dai ; Ming Xu ; Haiying Wu ; Lanjie Xue…
• 关键词：Simvastatin ; Osteoporosis ; Osteoblast ; Bone mineral density ; Animal model
• 刊名：Journal of Bone and Mineral Metabolism
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：34
• 期：1
• 页码：23-32
• 全文大小：1,097 KB
• 参考文献：1.Du Z, Chen J, Yan F, Xiao Y (2009) Effects of simvastatin on bone healing around titanium implants in osteoporotic rats. Clin Oral Implants Res 20:145–150PubMed CrossRef
  2.Lasota A, Danowska-Klonowska D (2004) Experimental osteoporosis–different methods of ovariectomy in female white rats. Rocz Akad Med Bialymst 49(Suppl 1):129–131PubMed
  3.Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4–S9PubMed CrossRef
  4.Shirke SS, Jadhav SR, Jagtap AG (2008) Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats. Exp Biol Med (Maywood) 233:1403–1410CrossRef
  5.Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916PubMed CrossRef
  6.Grey A, Reid IR (2005) Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs 14:265–278PubMed CrossRef
  7.Lane NE, Kelman A (2003) A review of anabolic therapies for osteoporosis. Arthritis Res Ther 5:214–222PubMed PubMedCentral CrossRef
  8.Dominguez LJ, Scalisi R, Barbagallo M (2010) Therapeutic options in osteoporosis. Acta Biomed 81(Suppl 1):55–65PubMed
  9.Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341PubMed CrossRef
  10.Reginster JY, Sarlet N (2006) The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol 5:15–23PubMed CrossRef
  11.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMed CrossRef
  12.Salari Sharif P, Abdollahi M, Larijani B (2011) Current, new and future treatments of osteoporosis. Rheumatol Int 31:289–300PubMed CrossRef
  13.Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210PubMed CrossRef
  14.Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216PubMed CrossRef
  15.Mundy G, Garrett R, Harris S, Chan J, Chen D et al (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949PubMed CrossRef
  16.Emmanuele L, Ortmann J, Doerflinger T, Traupe T, Barton M (2003) Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 302:67–72PubMed CrossRef
  17.Hatano H, Maruo A, Bolander ME, Sarkar G (2003) Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 8:842–848PubMed CrossRef
  18.Song C, Guo Z, Ma Q, Chen Z, Liu Z et al (2003) Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 308:458–462PubMed CrossRef
  19.Sugiyama M, Kodama T, Konishi K, Abe K, Asami S et al (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688–692PubMed CrossRef
  20.Izumo N, Fujita T, Nakamuta H, Koida M (2001) Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods Find Exp Clin Pharmacol 23:389–394PubMed CrossRef
  21.Li X, Cui Q, Kao C, Wang GJ, Balian G (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33:652–659PubMed CrossRef
  22.Wong RW, Rabie AB (2005) Early healing pattern of statin-induced osteogenesis. Br J Oral Maxillofac Surg 43:46–50PubMed CrossRef
  23.Alam S, Ueki K, Nakagawa K, Marukawa K, Hashiba Y et al (2009) Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:22–29PubMed CrossRef
  24.Rizzo M, Rini GB (2006) Statins, fracture risk, and bone remodeling: what is true? Am J Med Sci 332:55–60PubMed CrossRef
  25.Castaneda S, Largo R, Calvo E, Rodriguez-Salvanes F, Marcos ME et al (2006) Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. Skelet Radiol 35:34–41CrossRef
  26.Li GW, Tang GY, Liu Y, Tang RB, Peng YF et al (2012) MR spectroscopy and micro-CT in evaluation of osteoporosis model in rabbits: comparison with histopathology. Eur Radiol 22:923–929PubMed CrossRef
  27.Arens AM, Barr B, Puchalski SM, Poppenga R, Kulin RM et al (2011) Osteoporosis associated with pulmonary silicosis in an equine bone fragility syndrome. Vet Pathol 48:593–615PubMed CrossRef
  28.Zhang Y, Yu L, Ao M, Jin W (2006) Effect of ethanol extract of Lepidium meyenii Walp. on osteoporosis in ovariectomized rat. J Ethnopharmacol 105:274–279PubMed CrossRef
  29.Scholz-Ahrens KE, Delling G, Stampa B, Helfenstein A, Hahne HJ et al (2007) Glucocorticosteroid-induced osteoporosis in adult primiparous Gottingen miniature pigs: effects on bone mineral and mineral metabolism. Am J Physiol Endocrinol Metab 293:E385–E395PubMed CrossRef
  30.Liu X, Lei W, Wu Z, Cui Y, Han B et al (2012) Effects of glucocorticoid on BMD, micro-architecture and biomechanics of cancellous and cortical bone mass in OVX rabbits. Med Eng Phys 34:2–8PubMed CrossRef
  31.Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y et al (2010) Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop 81:396–401PubMed PubMedCentral CrossRef
  32.Schorlemmer S, Ignatius A, Claes L, Augat P (2005) Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 37:491–496PubMed CrossRef
  33.Akhter MP, Cullen DM, Gong G, Recker RR (2001) Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 29:121–125PubMed CrossRef
  34.Chen H, Wu M, Kubo KY (2012) Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats. J Ethnopharmacol 142:80–85PubMed CrossRef
  35.Hordon LD, Itoda M, Shore PA, Shore RC, Heald M et al (2006) Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT. Bone 38:444–449PubMed CrossRef
  36.Zhao FD, Pollintine P, Hole BD, Adams MA, Dolan P (2009) Vertebral fractures usually affect the cranial endplate because it is thinner and supported by less-dense trabecular bone. Bone 44:372–379PubMed CrossRef
  37.Li L, Zeng Z, Cai G (2011) Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine 18:985–989PubMed CrossRef
  38.Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW et al (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30:191–199PubMed CrossRef
  39.Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH et al (2009) Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39:296–303PubMed CrossRef
  40.Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609–618PubMed CrossRef
  41.Yin H, Shi ZG, Yu YS, Hu J, Wang R et al (2012) Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitricoxide formation in aged and ovariectomized rats. Eur J Pharmacol 674:200–206PubMed CrossRef
  42.Baek KH, Lee WY, Oh KW, Tae HJ, Lee JM et al (2005) The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci 20:438–444PubMed PubMedCentral CrossRef
  43.Hwang R, Lee EJ, Kim MH, Li SZ, Jin YJ et al (2004) Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatinon bone. J Biol Chem 279:21239–21247PubMed CrossRef
  44.Maeda T, Matsunuma A, Kawane T, Horiuchi N (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1cells. Biochem Biophys Res Commun 280:874–877PubMed CrossRef
  45.von Stechow D, Fish S, Yahalom D, Bab I, Chorev M et al (2003) Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord 4:8CrossRef
  46.Yazawa H, Zimmermann B, Asami Y, Bernimoulin JP (2005) Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J Periodontol 76:295–302PubMed CrossRef
  47.Chuang SC, Liao HJ, Li CJ, Wang GJ, Chang JK et al (2013) Simvastatin enhances human osteoblast proliferation involved in mitochondrial energy generation. Eur J Pharmacol 714:74–82PubMed CrossRef
  48.Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT (2006) BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21:637–646PubMed PubMedCentral CrossRef
  49.Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR et al (2003) BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278:34387–34394PubMed CrossRef
  50.Kim T, Ha H, Shim KS, Cho WK, Ma JY (2013) The anti-osteoporotic effect of Yijung-tang in an ovariectomized rat model mediated by inhibition of osteoclast differentiation. J Ethnopharmacol 146:83–89PubMed CrossRef
  51.Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H et al (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92:458–471PubMed CrossRef
  52.Liu XY, Zhang SS, Lu XM, Zheng SN, Li FM et al (2012) Metabonomic study on the anti-osteoporosis effect of Rhizoma Drynariae and its action mechanism using ultra-performance liquid chromatography-tandem mass spectrometry. J Ethnopharmacol 139:311–317PubMed CrossRef
  
• 作者单位：Lifen Dai (1) (2) (3)
  Ming Xu (1)
  Haiying Wu (4)
  Lanjie Xue (5)
  Dekai Yuan (1)
  Yuan Wang (1)
  Zhiqiang Shen (3)
  Hongbin Zhao (4)
  Min Hu (1) (2)
  
  1. Kunming Research Center for Molecular Medicine, Kunming University, Kunming, 650214, People’s Republic of China
  2. Department of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming, 650500, People’s Republic of China
  3. School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, 650500, People’s Republic of China
  4. Department of Emergency Medicine and Intensive Care Unit, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People’s Republic of China
  5. Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, People’s Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Metabolic Diseases
  Orthopedics
  Internal Medicine
  
• 出版者：Springer Japan
• ISSN：1435-5604

文摘

Osteoporosis is a systemic and metabolic bone disease. New drugs with good curative effect, fewer side effects, and high safety need to be developed urgently. Recently, simvastatin has been used to treat osteoporosis more frequently; however, its clinical effect and treatment mechanism are still unknown. With the use of animal models, the treatment effectiveness of simvastatin on experimental osteoporosis was investigated and the functional mechanism was preliminarily explored. The results show that simvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy-absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of simvastatin may be due to the promotion of proliferation and differentiation of osteoblasts. Simvastatin was effective in treating experimental osteoporosis. This study provides necessary experimental evidence for the clinical application of simvastatin in osteoporosis treatment. Keywords Simvastatin Osteoporosis Osteoblast Bone mineral density Animal model